PathoGenesis Corp.'s Phase II data for rifalazil to treat tuberculosis may have caused the stock to drop $5.5625 to $48.5625 on Wednesday as investors expressed their concerns that PGNS would become a one-product story. But the company believes that putting PA-1648 on the back burner in order to allocate resources to trials of its TOBI tobramycin formulation is a sound strategy. Left with one product in the clinic, PGNS expects earnings from sales of TOBI in cystic fibrosis and milestones from TOBI trials for additional